Tweets
Select your GCA Therapy
Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.
https://t.co/TPBeU7KaEq https://t.co/09uEzM3Kkd
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Predicting Palindromic Prognosis
Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria.
https://t.co/Nc0XymI24l https://t.co/69qdLh63ct
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Giant Cell Arteritis and Polymyalgia Rheumatica Update
Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria.
https://t.co/0V9Sle0GMU https://t.co/ixeT8L562C
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.
https://t.co/mv9DeZ9cez https://t.co/1OpT3MomO8
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Update on low-dose glucocorticoids in SLE
GC have been the mainstay of treatment in SLE for nearly 75 yrs. GC induce anti-inflammatory effects, quickly relieve symptoms, and reduce mortality in life-threatening flares through various actions.
https://t.co/uEtWftvwEz https://t.co/nJlpELMj5W
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Achieving drug-free remission in axSpA
In early axSpA, over 60% achieved sustained inactive disease. Male, non-smokers, low BASDAI scores had higher remission rates. Drug-free remission remains challenging.
https://t.co/Yv8a8C1hc9 https://t.co/JaYvfGry4P
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
POS0509 looks at time to diagnosis and #comorbidity burden in #axSpa
Retrospective study in French THIN database
Diagnostic delay remains common
Increased number of MSK & non-MSK manifestations & #comorbidities over time vs 1st presentation of back pain
#EULAR2024 @DrMiniDey https://t.co/egwDL1XjSw
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @Yuz6Yusof https://t.co/eSqOkBGBK2
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Proportion of ILD patients on IS drugs has massively increased over time!
Also good to see practices are changing & MTX is slowly creeping in
Anna Maria Hoffmann-Vold, ILD management session #EULAR2024 @AurelieRheumo https://t.co/npa8O7g7l8
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
PMR has distinct patterns on MRI shoulder, possibly helping Dx.
#EULAR2024 OP0248 @drdavidliew
also
@bmj_rmdopen
https://t.co/0J3xUmb9yt where they say:
"Similar to our prior findings... the target of inflammation in PMR is the outer covering of a tendon, the peritendineum" https://t.co/AzWkg3z2vR
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
How good are we at picking up depression in RA patients?
In this Polish registry:
- 1.8% had depression diagnosis
- 21% had low mood on HAQ
& depression has real correlates with disease activity.
Plenty to think about with truly holistic RA care!
#EULAR2024 POS1045 @drdavidliew https://t.co/ArfqHCKxhz
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Choices in GCA
https://t.co/e994wGiUwb https://t.co/psr9NV0OA6
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago


